Trevi Therapeutics ((TRVI)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Trevi Therapeutics recently completed a Phase 1 study titled ‘A Phase 1, Two-Part, Open-Label Drug-Drug Interaction Study to Evaluate the Steady State Pharmacokinetics and Safety Following Co-Administration of Nalbuphine Extended-Release Tablets (NAL ER), and Pirfenidone or Nintedanib in Healthy Adult Subjects.’ The study aimed to assess how steady-state NAL ER affects the pharmacokinetics of pirfenidone or nintedanib and vice versa in healthy participants. This research is significant as it could inform future treatment protocols involving these drugs.
The study tested the interaction of NAL ER, an oral tablet, with two other drugs: pirfenidone and nintedanib, both used in oral form. The goal was to understand the pharmacokinetic interactions between these medications when administered together.
The study employed a non-randomized, parallel intervention model without masking, focusing on treatment as its primary purpose. Participants were divided into four cohorts, receiving different combinations of the drugs to observe the interactions.
The study began on June 3, 2025, and was last updated on October 8, 2025. These dates are crucial as they mark the timeline of the study’s progress and completion, providing investors with a timeframe for potential market impacts.
The completion of this study could influence Trevi Therapeutics’ stock performance positively, as successful results may enhance the company’s drug portfolio. This development could also affect investor sentiment, especially in the context of competition within the pharmaceutical industry.
The study is now completed, with further details available on the ClinicalTrials portal.